A novel strategy for converting recombinant viral protein into high immunogenic antigen
- 19 August 1991
- journal article
- Published by Wiley in FEBS Letters
- Vol. 288 (1-2) , 138-142
- https://doi.org/10.1016/0014-5793(91)81020-9
Abstract
Interleukin 2 (IL-2) is a lymphokine promoting immune response and therefore has been investigated as an immunological adjuvant. In order to enhance the immunogenicity of recombinant viral protein, herpes simplex virus type 1 (HSV-1) glycoprotein D (gD), we genetically created a fusion protein consisting of gD and human IL-2. The fusion protein, without any other adjuvants, induced high antibody responses and cell-mediated immunity to HSV-1 in mice. Mice immunized with the fusion protein were protected against HSV-1 infection. The results indicate that IL-2-fusing can provide a means for converting a weak immunogenic protein into a high immunogenic antigen, and the strategy would be widely applicable to the other antigens for pathogens.Keywords
This publication has 8 references indexed in Scilit:
- Immunological adjuvants: a role for liposomesImmunology Today, 1990
- Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.Proceedings of the National Academy of Sciences, 1989
- Interleukin-2 Protects Neonatal Mice from Lethal Herpes Simplex Virus Infection: A Macrophage-Mediated, Interferon-Induced MechanismThe Journal of Infectious Diseases, 1989
- Immunological Adjuvants and VaccinesPublished by Springer Nature ,1989
- The establishment of IL-2 producing cells by genetic engineering.Cell Structure and Function, 1987
- An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunityJournal of Immunological Methods, 1986
- Comparison of the biological properties of purified natural and recombinant human interleukin-2Biochemical and Biophysical Research Communications, 1985
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970